Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma

Keren Harel-Dassa; Saul Yedgar; Claes G. Tropé; Ben Davidson; Reuven Reich

doi:10.1016/j.humpath.2016.12.023

Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma

Keren Harel-Dassa, Saul Yedgar, Claes G. Tropé, Ben Davidson, Reuven Reich^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The objective of this study was to analyze the expression and clinical role of phospholipase D (PLD) in high-grade serous carcinoma (HGSC). PLD1 and PLD2 isoform expression was studied in 125 HGSC specimens (73 effusions, 28 ovarian tumors, 24 solid metastases) using quantitative real-time reverse-transcription polymerase chain reaction. Expression levels were analyzed for association with clinicopathological parameters, including chemoresponse, and survival. PLD1 and PLD2 isoforms were found in most specimens at all anatomic sites, and their levels were strongly positively related (P < .001 for effusions and solid lesions). PLD2 messenger RNA (mRNA) expression was significantly higher in effusions compared with both carcinomas in the ovary and solid metastases (P < .001). Higher levels of both isoforms were associated with higher CA 125 levels at diagnosis (P < .001), and higher PLD2 mRNA levels in effusions were associated with unfavorable response to chemotherapy (P = .021). Expression levels of the studied isoforms were unrelated to the levels of previously studied mRNAs that form part of the phospholipase A₂ pathway or to survival. The present study provides the first evidence of PLD expression in HGSC and suggests a role in mediating progression to effusions and chemoresistance in this cancer.

Original language	English
Pages (from-to)	115-121
Number of pages	7
Journal	Human Pathology
Volume	62
DOIs	https://doi.org/10.1016/j.humpath.2016.12.023
State	Published - 1 Apr 2017

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Inc.

Keywords

Chemotherapy
High-grade serous carcinoma
Phospholipase D
Survival
Tumor progression

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.humpath.2016.12.023

Cite this

@article{163c4e7e14a14fdb972ce1aa035c7f7c,

title = "Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma",

abstract = "The objective of this study was to analyze the expression and clinical role of phospholipase D (PLD) in high-grade serous carcinoma (HGSC). PLD1 and PLD2 isoform expression was studied in 125 HGSC specimens (73 effusions, 28 ovarian tumors, 24 solid metastases) using quantitative real-time reverse-transcription polymerase chain reaction. Expression levels were analyzed for association with clinicopathological parameters, including chemoresponse, and survival. PLD1 and PLD2 isoforms were found in most specimens at all anatomic sites, and their levels were strongly positively related (P < .001 for effusions and solid lesions). PLD2 messenger RNA (mRNA) expression was significantly higher in effusions compared with both carcinomas in the ovary and solid metastases (P < .001). Higher levels of both isoforms were associated with higher CA 125 levels at diagnosis (P < .001), and higher PLD2 mRNA levels in effusions were associated with unfavorable response to chemotherapy (P = .021). Expression levels of the studied isoforms were unrelated to the levels of previously studied mRNAs that form part of the phospholipase A2 pathway or to survival. The present study provides the first evidence of PLD expression in HGSC and suggests a role in mediating progression to effusions and chemoresistance in this cancer.",

keywords = "Chemotherapy, High-grade serous carcinoma, Phospholipase D, Survival, Tumor progression",

author = "Keren Harel-Dassa and Saul Yedgar and Trop{\'e}, {Claes G.} and Ben Davidson and Reuven Reich",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = apr,

day = "1",

doi = "10.1016/j.humpath.2016.12.023",

language = "אנגלית",

volume = "62",

pages = "115--121",

journal = "Human Pathology",

issn = "0046-8177",

publisher = "W.B. Saunders",

}

TY - JOUR

T1 - Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma

AU - Harel-Dassa, Keren

AU - Yedgar, Saul

AU - Tropé, Claes G.

AU - Davidson, Ben

AU - Reich, Reuven

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The objective of this study was to analyze the expression and clinical role of phospholipase D (PLD) in high-grade serous carcinoma (HGSC). PLD1 and PLD2 isoform expression was studied in 125 HGSC specimens (73 effusions, 28 ovarian tumors, 24 solid metastases) using quantitative real-time reverse-transcription polymerase chain reaction. Expression levels were analyzed for association with clinicopathological parameters, including chemoresponse, and survival. PLD1 and PLD2 isoforms were found in most specimens at all anatomic sites, and their levels were strongly positively related (P < .001 for effusions and solid lesions). PLD2 messenger RNA (mRNA) expression was significantly higher in effusions compared with both carcinomas in the ovary and solid metastases (P < .001). Higher levels of both isoforms were associated with higher CA 125 levels at diagnosis (P < .001), and higher PLD2 mRNA levels in effusions were associated with unfavorable response to chemotherapy (P = .021). Expression levels of the studied isoforms were unrelated to the levels of previously studied mRNAs that form part of the phospholipase A2 pathway or to survival. The present study provides the first evidence of PLD expression in HGSC and suggests a role in mediating progression to effusions and chemoresistance in this cancer.

AB - The objective of this study was to analyze the expression and clinical role of phospholipase D (PLD) in high-grade serous carcinoma (HGSC). PLD1 and PLD2 isoform expression was studied in 125 HGSC specimens (73 effusions, 28 ovarian tumors, 24 solid metastases) using quantitative real-time reverse-transcription polymerase chain reaction. Expression levels were analyzed for association with clinicopathological parameters, including chemoresponse, and survival. PLD1 and PLD2 isoforms were found in most specimens at all anatomic sites, and their levels were strongly positively related (P < .001 for effusions and solid lesions). PLD2 messenger RNA (mRNA) expression was significantly higher in effusions compared with both carcinomas in the ovary and solid metastases (P < .001). Higher levels of both isoforms were associated with higher CA 125 levels at diagnosis (P < .001), and higher PLD2 mRNA levels in effusions were associated with unfavorable response to chemotherapy (P = .021). Expression levels of the studied isoforms were unrelated to the levels of previously studied mRNAs that form part of the phospholipase A2 pathway or to survival. The present study provides the first evidence of PLD expression in HGSC and suggests a role in mediating progression to effusions and chemoresistance in this cancer.

KW - Chemotherapy

KW - High-grade serous carcinoma

KW - Phospholipase D

KW - Survival

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=85015010849&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.12.023

DO - 10.1016/j.humpath.2016.12.023

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 28087476

AN - SCOPUS:85015010849

SN - 0046-8177

VL - 62

SP - 115

EP - 121

JO - Human Pathology

JF - Human Pathology

ER -

Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this